Real-world experience and clinical utility of a non-invasive gene expression rule-out test for melanoma and additional validation against high risk driver mutations in BRAF, NRAS and the TERT promoter. J of Skin [Internet]. 2018 Dec. 17 [cited 2025 Jun. 8];2:S69. Available from: https://skin.dermsquared.com/skin/article/view/465